AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Ticker:
4563
ISIN:
JP3127700007
Address:
Saito Bio-Incubator, (click to copy or hover over here to view full address)
CSRHub includes data on consequences of global warming, Lifestyle of health and sustainability, investment management, Community, environmental management, and ESG ratings.